Sugi Predict

Sugi Predict / Compounds / SCHEMBL4841484

SCHEMBL4841484

SCHEMBL4841484

COc1ccccc1N(CC(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ POLB P06746 3/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ITGA4 P13612 1/20 0.42
▸ ITGB7 P26010 1/20 0.42
▸ SNCA P37840 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPY1R P25929 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ PTGIR P43119 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MTNR1A P48039 1/20 0.38
▸ MTNR1B P49286 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6257485 0.83 AKR1B1 (0.39) KMT2AMEN1TDP1SMN1; SMN2
SCHEMBL1644746 0.83 TRPM8 (0.44) KMT2AMEN1POLBTDP1LMNA
SCHEMBL29943820 0.82 BCL2A1 (0.39) KMT2AMEN1POLBTDP1SMN1; SMN2
SCHEMBL4832843 0.82 BCL2A1 (0.39) KMT2AMEN1POLBTDP1SMN1; SMN2
SCHEMBL2921603 0.82 NPSR1 (0.39) KMT2AMEN1TDP1SMN1; SMN2NPSR1
SCHEMBL4832911 0.82 LMNA (0.41) POLBTDP1LMNAHTT
SCHEMBL26377716 0.81 MEN1 (0.42) KMT2AMEN1POLBSMN1; SMN2ITGA4
SCHEMBL4842133 0.81 SMN1; SMN2 (0.38) TDP1SMN1; SMN2NPSR1
SCHEMBL9133783 0.80 TDP1 (0.44) KMT2APOLBTDP1SMN1; SMN2LMNA
SCHEMBL24035759 0.80 GAA (0.41) KMT2AMEN1POLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351822-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2008-04-01 — — US disclosed
US-7053078-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2006-05-30 — — US disclosed
US-6946467-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-09-20 — — US disclosed
EP-1289954-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2005-09-14 — — EP disclosed
EP-1289953-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2005-09-07 — — EP disclosed
US-6936611-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-08-30 — — US disclosed
US-6900196-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-05-31 — — US disclosed
US-6878725-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-04-12 — — US disclosed
EP-1510515-A1 Phenylglycine derivatives as serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-03-02 — — EP disclosed
US-20040259868-A1 Serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-12-23 — — US disclosed
US-20040242656-A1 Serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-12-02 — — US disclosed
US-20040176363-A1 Serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-09-09 — — US disclosed
EP-1289950-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2004-09-08 — — EP disclosed
EP-1289972-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2004-09-08 — — EP disclosed
US-6784182-B2 AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS ELI LILLY AND COMPANY 2004-08-31 — — US disclosed
US-20040142963-A1 Serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-07-22 — — US disclosed
US-20030109706-A1 Serine pretease inhibitors ELI LILLY AND COMPANY 2003-06-12 — — US disclosed
US-20030078438-A1 Serine protease inhibitors ELI LILLY AND COMPANY 2003-04-24 — — US disclosed
US-20030055246-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-03-20 — — US disclosed
US-20020151724-A1 Serine protease inhibitors ELI LILLY AND COMPANY 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055246-A1 Serine protease inhibitors CTRL, CPN1, LOXL1 KMT2A 2452/4885MEN1 3582/4885POLB 2781/4885
US-20030109706-A1 Serine pretease inhibitors PRSS1, SERPINE1, HPN KMT2A 3428/4885MEN1 1712/4885POLB 3710/4885
US-20040259868-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 KMT2A 3308/4885MEN1 1959/4885POLB 4543/4885
US-20030078438-A1 Serine protease inhibitors HPN, LPXN, PRSS1 KMT2A 2897/4885MEN1 3220/4885POLB 4589/4885
US-20040142963-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 KMT2A 3308/4885MEN1 1959/4885POLB 4543/4885
US-20020151724-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 KMT2A 3308/4885MEN1 1959/4885POLB 4543/4885
US-20040176363-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 KMT2A 3308/4885MEN1 1959/4885POLB 4543/4885
US-20040242656-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 KMT2A 3308/4885MEN1 1959/4885POLB 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.